Is insulin degludec a more effective treatment for patients using high doses of insulin glargine but not attaining euglycemia? Some case reports from India

References

• No authors listed UK Prospective Diabetes Study 16: overview of 6 years’ therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group Diabetes 1995 44 11 1249 1258 7589820
   PubMed Web of Science ®Google Scholar
• Heise T Nosek L Bøttcher SG Hastrup H Haahr H Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes Diabetes Obes Metab 2012 14 10 944 950 22726241
   PubMed Web of Science ®Google Scholar
• Ashwell SG Gebbie J Home PD Twice-daily compared with once-daily insulin glargine in people with type 1 diabetes using meal-time insulin aspart Diabet Med 2006 23 8 879 886 16911626
   PubMed Web of Science ®Google Scholar
• Housel AK Shaw RF Waterbury NV Glucose control in patients with type 2 diabetes based on frequency of insulin glargine administration Diabetes Res Clin Pract 2010 8 2 17 19
   Google Scholar
• Floch JL Levy M Mosnier-Pudar H Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes assessment of detemir administration in a progressive treat-to-target trial (ADAPT) Diabetes Care 2009 32 1 32 37 18945928
   PubMed Web of Science ®Google Scholar
• Mayfield J White R Insulin therapy for type 2 diabetes: rescue, augmentation and replacement of beta-cell function Am Fam Physician 2004 70 3 489 500 15317436
   PubMed Web of Science ®Google Scholar
• Kurtzhals P Heise T Strauss HM Multi-hexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec Diabetologia 2011 54 Suppl 1 S426
   Google Scholar
• Jonassen I Havelund S Hoeg-Jensen T Steensgaard DB Wahlund PO Ribel U Design of the novel protraction mechanism of insulin degludec, ultra-long-acting basal insulin Pharm Res 2012 29 8 2104 2114 22485010
   PubMed Web of Science ®Google Scholar
• Heise T Hermanski L Nosek L Feldman A Rasmussen S Haahr H Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes Diabetes Obes Metab 2012 14 9 859 864 22594461
   PubMed Web of Science ®Google Scholar
• Keating GM Insulin degludec and insulin degludec/insulin aspart: a guide to their use in diabetes mellitus Drugs 2013 73 6 575 593 23620200
   PubMed Web of Science ®Google Scholar
• Rodbard HW Gough S Lane W Korsholm L Bretler DM Handelsman Y Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients of type 2 diabetes requiring high doses of basal insulin: meta-analysis of five randomized BEGIN® trials Endocr Pract 2013 20 4 285 290 24246344
   PubMed Web of Science ®Google Scholar
• Heller S Buse J Fisher M Insulin degludec, an ultra-long acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN® Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial Lancet 2012 379 9825 1489 1497 22521071
   PubMed Web of Science ®Google Scholar
• Mathieu C Hollander P Miranda-Palma B Efficacy and safety of insulin degludec in a flexible dosing regimen vs. insulin glargine in patients with type 1 diabetes (BEGIN®: Flex T1): a 26-week randomized treat-to-target trial with a 26-week extension J Clin Endocrinol Metab 2013 98 3 1154 1162 23393185
   PubMed Web of Science ®Google Scholar
• Zinman B Philis-Tsimikas A Cariou B Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN® Once Long) Diabetes Care 2012 35 12 2464 2471 23043166
   PubMed Web of Science ®Google Scholar
• Garber AJ King AB Del Prato S Insulin degludec, an ultra-long acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN® Basal-Bolus Type 2): a phase 3, randomized, open-label, treat-to-target non-inferiority trial Lancet 2012 379 9825 1498 1507 22521072
   PubMed Web of Science ®Google Scholar
• Onishi Y Iwamoto Y Yoo SJ Clauson P Tamer SC Park S Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: a 26-week, randomized, controlled, Pan Asian, treat-to-target trial J Diabetes Invest 2013 4 6 605 612
   PubMed Web of Science ®Google Scholar
• Meneghini L Atkin SL Gough SC The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes Diabetes Care 2013 36 4 858 864 23340894
   PubMed Web of Science ®Google Scholar
• Gough S Bhargava A Jain R Mersebach H Rasmussen S Bergenstal RM Low volume insulin degludec 200 U/mL once-daily improves glycemic control similar to insulin glargine with a low risk of hypoglycemia in insulin-naïve patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN® LOW VOLUME trial Diabetes Care 2013 36 9 2536 2542 23715753
   PubMed Web of Science ®Google Scholar
• Singh AK Sinha B Advances in basal insulin therapy: lessons from current evidence J Indian Med Assoc 2013 111 11 735 742 24968481
   PubMedGoogle Scholar